DiSaia Philip J, Bloss Jeffrey D
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, College of Medicine, Orange, CA 92868-3298, USA.
Gynecol Oncol. 2003 Aug;90(2 Pt 2):S24-32. doi: 10.1016/s0090-8258(03)00341-x.
The objective was to review the progress made in gene- and molecular-based management of ovarian cancer over the past decade and the future direction of targeted therapies.
Research studies, review articles, and scientific meeting abstracts published between 1994 and 2002 were reviewed and analyzed.
Significant progress has been made in understanding the molecular biology of ovarian cancer and the role that single-nucleotide polymorphisms, tumor suppressor genes, and oncogenes play in promoting tumor cell growth and proliferation. Strategies have been developed to correct gene defects or single out ovarian cancer cells for destruction. Molecular-based therapies are now under development to specifically target receptors and signal transduction pathways that control cell proliferation and apoptosis, angiogenesis, cellular adhesion, and cell motility in ovarian tumors.
The end product of this intense investigation will be new targeted therapies that offer the hope of improving the medical management of ovarian cancer while being significantly less toxic to normal cells.
回顾过去十年间在卵巢癌基因和分子治疗方面取得的进展以及靶向治疗的未来方向。
对1994年至2002年间发表的研究报告、综述文章及科学会议摘要进行回顾与分析。
在了解卵巢癌分子生物学以及单核苷酸多态性、肿瘤抑制基因和癌基因在促进肿瘤细胞生长和增殖中所起的作用方面已取得显著进展。已制定出纠正基因缺陷或挑选出卵巢癌细胞进行破坏的策略。基于分子的疗法目前正在研发中，以特异性靶向控制卵巢肿瘤细胞增殖和凋亡、血管生成、细胞黏附和细胞运动的受体及信号转导通路。
这一深入研究的最终成果将是新的靶向疗法，有望改善卵巢癌的医疗管理，同时对正常细胞的毒性显著降低。
